With a market capitalization of over $800 billion, Eli Lilly (NYSE: LLY) is the largest pharmaceutical company in the world.

Eli Lilly’s stock has climbed almost 60% this year and trades for more than $900. The pharma giant also has seen soaring ...

Eli Lilly's long-term growth prospects are strong with improved supply, new growth opportunities, and competitive positioning ...

An analysis of Eli Lilly's stock reveals high premium, overvaluation concerns and a low dividend yield. LLY is rated hold due ...

Company is investing $2.8bn in two Irish plants to produce its in-demand weight loss drugs and a new Alzheimer’s therapy ...

(Reuters) - Eli Lilly is investing $1.8 billion across two manufacturing sites in Ireland to boost production of its hugely ...

The Federal Trade Commission is suing the three largest prescription drug benefit managers (PBMs) for allegedly driving up ...

The Government is expected to perform a U-turn in the budget by scrapping plans to impose a capital gains tax (CGT) liability ...

Eli Lilly reduces price of weight loss medicine Zepbound, offering discounts to patients. Obesity rates skyrocket in America.

Anyone who stops in for a cup of coffee or to enjoy their morning is invited to help add a swath of fabric fringe to a wall ...

The stock's rise snapped a four-day losing streak.

Pharmaceutical heavyweights like Bristol Myers Squibb, AstraZeneca, and Eli Lilly are betting big on radiopharmaceuticals, ...